Abstract: Aspects of the present disclosure relate to novel medical compositions and methods of using same. In certain aspects, the disclosure relates to methods preventing acute kidney injury in a patient associated with increased amount of protein in the urine (e.g. albuminuria). In certain embodiments, the disclosure provides methods of preventing or treating acute kidney injury in a patient receiving a nephrotoxic drug, by administration of a reversible endocytosis inhibitor.

Abstract: A charge detection mass spectrometer may include an ion source to generate ions, a mass spectrometer to separate the generated ions as a function of ion mass-to-charge ratio to produce beam of separated ions, an electrostatic linear ion trap (ELIT) including a charge detection cylinder disposed between a pair of coaxially aligned ion mirrors, and means for controlling a trajectory of the beam of separated ions entering the ELIT to cause the ions subsequently trapped in the ELIT to oscillate therein with different planar ion oscillation trajectories angularly offset from one another about the longitudinal axis with each extending along and crossing the longitudinal axis in each of the ion mirrors or with different cylindrical ion oscillation trajectories radially offset from one another about the longitudinal axis to form nested cylindrical trajectories each extending along the longitudinal axis.

Abstract: Disclosed are methods to treat a renal disorder in a mammal in need thereof by administering to the mammal in need of treatment an effective amount of a store operated calcium entry (SOCE) inhibitor or a pharmaceutically acceptable salt thereof.

Abstract: The device of the present disclosure is configured for laparoscopic use, particularly to insert a fastener into a plate at an angle of up to 180° from the plane of insertion. The device is further configured to carry a plurality of fasteners, a tightening tool, a cutting device, and tweezers simultaneously to facilitate a rapid procedure while lessening the chance of infection by limiting the amount of times the device must be removed and re-inserted.

Abstract: A method for analyzing charged particles may include generating, in or into an ion source region, charged particles from a sample of particles, causing the charged particles to enter a mass spectrometer from the ion source region at each of a plurality of differing physical and/or chemical conditions in a range of physical and/or chemical conditions in which the sample particles undergo structural changes, controlling the mass spectrometer to measure at least the charge magnitudes of the generated charged particles at each of the plurality of differing physical and/or chemical conditions, determining, with a processor, an average charge magnitude of the generated charged particles at each of the plurality of differing physical and/or chemical conditions based on the measured charge magnitudes, and determining, with the processor, an average charge magnitude profile over the range of physical and/or chemical conditions based on the determined average charge magnitudes.

Abstract: A training method and device for estimating depth information of an image are disclosed. The training method may include obtaining depth information of a first image according to a resolution based on the first image, and outputting a per-pixel depth error of the first image based on the depth information of the first image, depth information of a second image, and camera parameters.

Abstract: Modified DDAH polypeptides and their uses thereof are provided. Exemplary embodiments provide DDAH polypeptides which include one or more amino acid substitutions, additions, or deletions with natural or non-naturally encoded amino acids, and/or linkage to other biologically active molecules including other DDAH polypeptides, as well as PKEM. Additionally, use of said DDAH polypeptides for treatment of disease, such as heart failure or renal disease, is also provided.

Abstract: An improved nanocomposite cathode material for lithium-ion batteries and method of making the same. The nanocomposite cathode material includes lithium iron silicate based nanoparticles with a conductive matrix of graphene sheets. The nanoparticles may be doped with at least one anion or cation.

Abstract: Disclosed herein are mass spectrometry sample substrates. Also disclosed herein are mass spectrometry sample strips and cartridges that include a solid phase extraction (SPE) element. The mass spectrometry sample substrates, sample strips, and cartridges can be used in paper spray mass spectrometry to detect and quantify one or more analytes present in a biological sample. Also disclosed are methods for collecting and concentrating one or more analytes from a biological sample, as well as for storing a biological sample that includes one or more analytes. Methods for analyzing the one or more analytes from the biological sample are also provided.

Abstract: Disclosed herein are methods for producing interfering RNA biopesticides, such as microbial host organisms engineered to produce interfering RNA molecules which inhibit the expression of a gene in a mosquito disease vectors by RNA interference. Also disclosed herein are polynucleotides, such as expression cassettes encoding such interfering RNA molecule and facilitating integration, such as stable integration into the host organism's genome. Further disclosed herein are compositions including the disclosed nucleotide sequences and host organisms, along with methods of using the same to control mosquito populations.

Abstract: Disclosed herein are methods for using dual amplification of MYC and HSF1 in cancer cells to identify cancer cells having increased susceptibility to a therapeutic inhibitor. Disclosed herein are methods for treating a patient with cancer where the cancer cells have coamplification of MYC and HSF1. Also disclosed are methods for identifying therapeutic target and therapeutic compounds by screening with cells known to have dual amplification of MYC and HSF1.

Abstract: A TAT-FXN fusion polypeptide useful in treating subjects diagnosed with Friedrich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.

Abstract: A charge detection mass spectrometer (CDMS) includes an electrostatic linear ion trap (ELIT), a processor, and a memory having instructions stored therein executable by the processor to (a) control the ELIT to trap an ion, (b) collect ion measurement information as the trapped ion oscillates back and forth through the ELIT, the ion measurement information including charge induced by the ion on a charge detector of the ELIT during each pass of the ion through the ELIT and timing of the induced charges relative to one another, (c) process the ion measurement information in the time-domain for each of a plurality of sequential time windows of the ion measurement information to determine a charge magnitude of the ion during each time window, and (d) determine the magnitude of charge of the trapped ion based on the charge magnitudes of each of the time windows.

Abstract: Embodiments herein report compositions, methods, uses and manufacturing procedures for rotavirus constructs and immunogenic compositions thereof. Some embodiments concern compositions that include, but are not limited to, chimeric rotaviruses of use in immunogenic compositions against rotavirus infection as well as against other pathogenic virus infection in a subject. In certain embodiments, constructs of use herein can be generated and used where a rotavirus expression system further includes one or more nucleic acid molecules encoding one or more polypeptides of another pathogen (e.g. another enteric or mucosal pathogen).

Abstract: An electrostatic linear ion trap (ELIT) array includes a plurality of ion mirrors and a plurality of elongated charge detection cylinders each defining an axial passageway centrally therethrough, the ion mirrors and the charge detection cylinders arranged relative to one another such that each charge detection cylinder is positioned between a different respective pair of the ion mirrors with the respective axial passageways of each coaxial with one another, wherein the axial passageways of the ELITs are not coaxial with one another, means for selectively directing at least one ion into each of the plurality of ELITs, and means for controlling each of the ion mirrors in a manner which causes the at least one ion in at least two of the ELITs to become trapped therein and to simultaneously oscillate back and forth between the respective ion mirrors each time passing through the respective charge detection cylinder.

Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

Abstract: A TAT-FXN fusion polypeptide useful in treating subjects diagnosed with Friedrich's Ataxia, hypertrophic cardiomyopathy, or both are disclosed, as are related methods of treatment and pharmaceutical compositions.

Abstract: A charge detection mass spectrometer includes an ion trap configured to receive and store ions therein and to selectively release stored ions therefrom, and an electrostatic linear ion trap (ELIT) spaced apart from the ion trap, the ELIT including first and second ion mirrors and a charge detection cylinder positioned therebetween, and means for selectively controlling the ion trap to release at least some of the stored ions therefrom to travel toward and into the ELIT, and for controlling the first and second ion mirrors in a manner which traps in the ELIT a single one of the ions traveling therein and causes the trapped ion to oscillate back and forth between the first and second ion mirrors each time passing through and inducing a corresponding charge on the charge detection cylinder.

Abstract: Methods of treating a disease, disorder or syndrome associated with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (such as COVID-19) in a subject by administering one or more C-X-C chemokine receptor 3 (CXCR3) antagonist peptides are described. Diagnostic methods for enhancing replication of SARS-CoV-2 in cultured cells and/or detecting the presence of SARS-CoV-2 in cultured cells by contacting the cells with a CXCR3 agonist peptide are also described.

Abstract: A method of producing bioengineered tissue includes coating a microstructured fiber with a bioink containing a plurality of living cells. The microstructured fiber is embedded with microfluidic channels defining periodic outlet apertures, a plurality of ultrasonic transducers, at least one chemical sensor, and at least one temperature sensor. The method further includes applying the coated fiber to an anatomic model of an organ. The microfluidic channels and outlet apertures of the fiber are configured to function as an artificial blood-vessel system to the bioengineered tissue, thereby supplying building material for the proliferation of the plurality of living cells, and allowing the bioengineered tissue to mature into functional tissue.